We are developing and delivering photo-crosslinked, biodegradable ocular drug delivery systems engineered to provide 6 months + sustained release for a broad range of therapeutic modalities, including Biologics, Peptides, Large and Small Molecules.
Through innovative sustained-release therapeutics, we aim to resolve the treatment burden of frequent intravitreal injections and improve the quality of care for patients with sight-threatening diseases.
Re-Vana is working with several global pharmaceutical companies in conducting preformulation and preclinical feasibility studies.
